Approval · Notice of Compliance 36679 · 2026
REDEMPLO: Notice of Compliance 36679
Issued January 2, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36679
- Date
- January 2, 2026
- Company
- Arrowhead Pharmaceuticals, Inc.Pasadena, California, United States
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REDEMPLO | 02564327 | Marketed |
Medicinal ingredients
- PLOZASIRAN 25 MG per 0.5ML